Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
streptozocin + procarbazine + lomustine + prednisone + vincristine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Streptozocin + procarbazine + lomustine + prednisone + vincristine** is an unbranded multi-agent cytotoxic chemotherapy regimen specified by its five separate active ingredients, rather than a single co-formulated medicinal product with a distinct nonproprietary name. Streptozocin, procarbazine, and lomustine are DNA-damaging alkylating or methylating agents; vincristine disrupts mitotic spindle formation by binding tubulin and inhibiting microtubule assembly; and prednisone is a glucocorticoid receptor agonist with lympholytic and anti-inflammatory effects. The exact five-drug combination could not be confirmed as a named, registered regimen in the public sources reviewed and should not be conflated with PCV, which contains procarbazine, lomustine, and vincristine, or MOPP, which contains mechlorethamine, vincristine, procarbazine, and prednisone. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00052455))
- Other names
- lomustine + prednisone + procarbazine + streptozocin + vincristinestreptozocin + procarbazine + lomustine + prednisone + vincristinestreptozotocin + procarbazine + lomustine + prednisone + vincristine
02
Targets
TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on streptozocin + procarbazine + lomustine + prednisone + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on streptozocin + procarbazine + lomustine + prednisone + vincristine.